Bicara Therapeutics (NASDAQ:BCAX) Earns Market Perform Rating from Analysts at Citizens Jmp

Equities researchers at Citizens Jmp initiated coverage on shares of Bicara Therapeutics (NASDAQ:BCAX) in a report issued on Thursday. The firm set a “market perform” rating and a $31.00 price target on the stock. Citizens Jmp’s target price would suggest a potential upside of 86.86% from the company’s current price.

BCAX has been the subject of several other research reports. BTIG Research reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research report on Thursday, January 15th. Wedbush reissued an “outperform” rating and set a $30.00 price target on shares of Bicara Therapeutics in a research report on Tuesday, January 13th. HC Wainwright reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Mizuho upgraded shares of Bicara Therapeutics to a “hold” rating in a research note on Thursday, December 18th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Friday, January 9th. Seven analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $28.33.

Bicara Therapeutics Trading Down 1.1%

Shares of BCAX stock opened at $16.59 on Thursday. The company has a market cap of $908.80 million, a PE ratio of -7.41 and a beta of -0.79. The company’s fifty day simple moving average is $17.53 and its 200-day simple moving average is $14.83. Bicara Therapeutics has a 52 week low of $7.80 and a 52 week high of $19.71.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.12). Equities research analysts expect that Bicara Therapeutics will post -2.59 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Ivan Hyep sold 1,882 shares of Bicara Therapeutics stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $18.15, for a total value of $34,158.30. Following the completion of the sale, the chief financial officer owned 145,355 shares in the company, valued at approximately $2,638,193.25. The trade was a 1.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Ryan Cohlhepp sold 3,828 shares of the stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $18.10, for a total transaction of $69,286.80. Following the transaction, the chief operating officer owned 210,164 shares in the company, valued at $3,803,968.40. This trade represents a 1.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 95,922 shares of company stock valued at $1,784,142 over the last 90 days.

Institutional Investors Weigh In On Bicara Therapeutics

Institutional investors have recently modified their holdings of the stock. Legal & General Group Plc grew its stake in Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after purchasing an additional 1,233 shares in the last quarter. Ameritas Investment Partners Inc. lifted its holdings in Bicara Therapeutics by 73.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after buying an additional 1,474 shares during the last quarter. Invesco Ltd. lifted its holdings in Bicara Therapeutics by 13.2% during the 2nd quarter. Invesco Ltd. now owns 16,877 shares of the company’s stock worth $157,000 after buying an additional 1,962 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Bicara Therapeutics in the 4th quarter worth approximately $45,000. Finally, Avanza Fonder AB increased its holdings in shares of Bicara Therapeutics by 42.7% in the 3rd quarter. Avanza Fonder AB now owns 9,371 shares of the company’s stock valued at $148,000 after acquiring an additional 2,804 shares during the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.